Wellington Management Group LLP Increases Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Wellington Management Group LLP grew its stake in Royalty Pharma plc (NASDAQ:RPRX) by 4.1% during the fourth quarter, HoldingsChannel reports. The firm owned 18,539 shares of the biopharmaceutical company’s stock after purchasing an additional 733 shares during the quarter. Wellington Management Group LLP’s holdings in Royalty Pharma were worth $473,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Brooklyn Investment Group grew its position in Royalty Pharma by 1,006.9% in the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 876 shares during the last quarter. Allworth Financial LP lifted its stake in shares of Royalty Pharma by 417.6% in the 4th quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 877 shares during the period. Riverview Trust Co lifted its stake in shares of Royalty Pharma by 3,953.3% in the 4th quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 1,186 shares during the period. Fifth Third Bancorp boosted its holdings in shares of Royalty Pharma by 187.1% in the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 997 shares in the last quarter. Finally, Blue Trust Inc. increased its stake in shares of Royalty Pharma by 31.3% during the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 376 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Analyst Upgrades and Downgrades

RPRX has been the subject of a number of recent analyst reports. Citigroup restated a “buy” rating on shares of Royalty Pharma in a research report on Friday, March 28th. TD Cowen raised Royalty Pharma to a “strong-buy” rating in a report on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $42.50.

Royalty Pharma Stock Up 1.1 %

Shares of NASDAQ RPRX opened at $32.29 on Tuesday. The stock has a market capitalization of $18.61 billion, a price-to-earnings ratio of 22.27, a price-to-earnings-growth ratio of 2.31 and a beta of 0.50. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.20. The firm has a 50-day moving average price of $32.52 and a 200 day moving average price of $29.17. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.64.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. Equities research analysts anticipate that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.